While the increase in cardiovascular risk factors is at least partially due to the obesity epidemic, the researchers believe the increase is multifactorial.
Risks of adverse cardiovascular-related outcomes or mortality are not reduced with CPAP treatment.
Clinicians should make patients aware of their increased risk for stroke and heart attack.
Men who received testosterone replacement therapy had lower odds of cardiovascular events.
Previous research has suggested that statins and PCSK9 inhibitors may adversely affect cognition.
Standardized definitions were proposed for stroke, hypoxic-ischemic injury, and cerebral hemorrhage.
Early intervention in patients with heart failure or atrial fibrillation may help delay or prevent the onset of mild dementia.
Patients receiving treatment with vitamin K antagonists (VKA) or antiplatelet agents face a significantly increased risk of mortality within 24 hours of intracranial hemorrhage.
A significant inverse trend was observed between the Healthy Nordic Food Index and risk of stroke.
Patients with elevated levels of activity in the amygdala were at higher risk for cardiovascular events.
Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.
Patients experienced a 34% risk of a reduction in the ability to perform daily tasks independently.
Amyloid beta protein accumulation was present in the hearts of patients with Alzheimer's disease.
Half of patients experienced a reduction in seizure frequency after statin initiation.
Women with a history of migraine headache had a more than 2-fold increased risk of stroke over a 6-year follow-up period.
Those with previous cognitive impairment saw a more pronounced improvement.
Patients with Alzheimer's disease tended to have increased thickness in the wall of their left ventricle.
The effect of antihypertensive drugs and stains on cognition is uncertain.
Long episodes of AT/AF were more likely to be associated with clinical events than short episodes.
A committee from the American Heart Association failed to make specific clinical recommendations for the management of hypertension related to cognitive impairment.
Vascular disease can have a negative impact on cognition and motor phenotype in PD.
At baseline, 83% of the patients had established cardiovascular disease, chronic kidney disease, or both.
In subjects with a low risk of preclinical Alzheimer's disease indexed by the absence of MTA, findings were confirmed.
The researchers noted that CPAP users may not be using the device long enough to see benefits for their cardiovascular health.
Studies have linked GCA with increased risk of VTE; however, results have been compromised by limited data sets.
Doctors should be monitoring for high blood pressure and cholesterol in this patient population.
Both lesion count and volume was less in the treatment group vs controls.
All but one type of statin was associated with a dose-dependent neurprotective benefit against Parkinson's.
Cases of all-cause dementia and Alzheimer's did not significantly differ between study groups.
There was no difference in risk of stroke or mortality between hypertensive groups.
Neurology Advisor Articles
- Coffee Consumption May Decrease Stroke Risk
- Prochlorperazine More Effective Than Ketamine for Headache Relief in the Emergency Department
- CTE Confirmed With Antemortem PET Imaging, Autopsy in Professional Football Player
- Intranasal Sumatriptan More Effectively Reduces Migraine-Associated Nausea
- Neuropsychiatric Conditions Common in Relatives of Patients With Amyotrophic Lateral Sclerosis
- Treating Cluster Headache: Weighing Current Therapies
- Alzheimer Disease Linked to High Cumulative Doses of Zolpidem in Elderly
- NBT System Gets FDA Clearance for Depression Treatment
- Better Migraine Pain Relief With IV Non-Opioid Combination vs IV Hydromorphone
- FDA Approves Myasthenia Gravis Treatment
- Reports of Agranulocytosis Prompt Monitoring for Investigational Parkinson's Drug
- Nusinersen Improves Motor Function, Survival in Infants With Spinal Muscular Atrophy
- Noninvasive Brain Stimulation System Approved for Depression
- Hypertension Guidelines Updated by AHA/ACA
- Bone Mineral Density Associated With Intracranial Aneurysm Presence, Size